NASDAQ:ORKA Oruka Therapeutics (ORKA) Stock Price, News & Analysis $92.38 +0.73 (+0.80%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$92.36 -0.02 (-0.03%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Oruka Therapeutics Stock (NASDAQ:ORKA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oruka Therapeutics alerts:Sign Up Key Stats Today's Range$90.48▼$94.2950-Day Range$83.04▼$113.0852-Week Range$14.66▼$115.51Volume585,299 shsAverage Volume751,435 shsMarket Capitalization$6.12 billionP/E RatioN/ADividend YieldN/APrice Target$133.00Consensus RatingModerate Buy Company Overview Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments. Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17. These programs remain in clinical development and have not been approved for commercial use. The company was formed through a business combination involving ARCA biopharma and Oruka Therapeutics and operates as Oruka Therapeutics, Inc. Its activities are focused on advancing its proprietary antibody platform and development programs, primarily for patients with chronic immune-mediated diseases.AI Generated. May Contain Errors. Read More Oruka Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreORKA MarketRank™: Oruka Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 282nd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOruka Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOruka Therapeutics has a consensus price target of $133.00, representing about 44.0% upside from its current price of $92.38.Amount of Analyst CoverageOruka Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Oruka Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oruka Therapeutics are expected to decrease in the coming year, from ($2.42) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oruka Therapeutics is -45.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oruka Therapeutics is -45.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOruka Therapeutics has a P/B Ratio of 9.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oruka Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.39% of the float of Oruka Therapeutics has been sold short.Short Interest Ratio / Days to CoverOruka Therapeutics has a short interest ratio ("days to cover") of 9.27.Change versus previous monthShort interest in Oruka Therapeutics has recently decreased by 6.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOruka Therapeutics does not currently pay a dividend.Dividend GrowthOruka Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment-0.07 News SentimentOruka Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Oruka Therapeutics this week, compared to 5 articles on an average week.Search Interest4 people have searched for ORKA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows4 people have added Oruka Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oruka Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,951,678.00 in company stock.Percentage Held by Insiders23.49% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oruka Therapeutics' insider trading history. Receive ORKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORKA Stock News HeadlinesAnalysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Jazz Pharmaceuticals (JAZZ)September 10 at 7:26 PM | theglobeandmail.comOruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare ConferenceSeptember 9 at 4:01 PM | globenewswire.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.September 12 at 1:00 AM | Paradigm Press (Ad)HC Wainwright Cuts Earnings Estimates for Oruka TherapeuticsSeptember 7, 2026 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)September 5, 2026 | americanbankingnews.comInsider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells 75,000 Shares of StockSeptember 2, 2026 | insidertrades.comInsider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $782,880.00 in StockAugust 18, 2026 | insidertrades.comOruka Therapeutics (NASDAQ:ORKA) SVP Sells 10,000 Shares of StockAugust 15, 2026 | insidertrades.comSee More Headlines ORKA Stock Analysis - Frequently Asked Questions How have ORKA shares performed this year? Oruka Therapeutics' stock was trading at $30.31 at the beginning of the year. Since then, ORKA stock has increased by 204.8% and is now trading at $92.38. How were Oruka Therapeutics' earnings last quarter? Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced its quarterly earnings data on Monday, August, 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.04. Who are Oruka Therapeutics' major shareholders? Oruka Therapeutics' top institutional investors include BlackRock Inc. (8.27%), California State Teachers Retirement System (5.18%), Jupiter Topco LLC (2.08%) and Bank of America Corp DE (0.53%). Insiders that own company stock include Venrock Healthcare Capital Par, Fairmount Funds Management Llc, Lawrence Otto Klein, Carl Dambkowski, Joana Goncalves and Arjun Agarwal. View institutional ownership trends. How do I buy shares of Oruka Therapeutics? Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oruka Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and NuScale Power (SMR). Company Calendar Last Earnings8/10/2026Today9/12/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ORKA's financial health is in the Green zone, according to TradeSmith. ORKA has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ORKA Previous SymbolNASDAQ:ORKA CIK907654 Webwww.orukatx.com Phone(650) 606-7910Fax720-208-9261Employees68Year FoundedN/APrice Target and Rating Average Price Target for Oruka Therapeutics$133.00 High Price Target$200.00 Low Price Target$45.00 Potential Upside/Downside+44.0%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.65% Return on Assets-20.88% Debt Debt-to-Equity RatioN/A Current Ratio38.51 Quick Ratio38.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.69 per share Price / Book9.53Miscellaneous Outstanding Shares66,210,000Free Float50,657,000Market Cap$6.12 billion OptionableN/A Beta-0.34 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:ORKA) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our Partners100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe retirement income that answers “yes” when everything else says noTodd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...Eagle Publishing | Sponsored17 Nobel Prize winners… one startling warningOn July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...Porter & Company | SponsoredI called NVDA at $6 - Here's what’s next…Matt McCall called NVDA at 6 dollars - it's since climbed more than 3,100 percent. He's identified 51 stocks t...Monument Traders Alliance | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
